Oncology Journal

Overview

publication venue for

• A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. 1985
• Are breakpoints variable on the long arm of chromosome 5 (5q-) in patients with refractory anemia? 1984
• Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health..  98. 2020
• Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care..  93. 2017
• Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma..  90. 2016
• Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061..  90. 2015
• Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib..  89. 2015
• Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma..  89. 2015
• Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial..  88. 2015
• Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients..  88. 2014
• An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma..  87. 2014
• Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease..  86. 2014
• Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)..  85. 2013
• Impact of age on the management of primary melanoma patients..  85. 2013
• Enrollment in clinical trials correlates with improved survival in metastatic melanoma..  81. 2012
• Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients..  81. 2011
• Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors..  81. 2011
• A high proliferative index of recurrent melanoma is associated with worse survival..  80. 2011
• Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?.  80. 2011
• Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis..  80. 2011
• The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma..  78. 2010
• Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience..  77. 2009
• Elevated serum leptin levels: a risk factor for non-small-cell lung cancer?.  76. 2008
• Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study..  74. 2008
• Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results..  72. 2007
• Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma..  71. 2007
• Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer..  68. 2005
• Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel..  64. 2003
• Estrogens, testosterone and sex hormone binding globulin in relation to liver cancer in men..  60. 2001
• Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer..  51 Suppl 1. 1994
• Doxorubicin and etoposide in the treatment of advanced measurable breast cancer..  47. 1990
• Phase II study of esorubicin in the treatment of patients with advanced sarcoma..  46. 1989
• Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing..  45. 1988
• High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study..  45. 1988
• Phase II trial of mitoxantrone in advanced gastric cancer..  45. 1988
• Prognostic significance of changes in serum transcobalamin levels in cancer patients with chemotherapy-induced granulocytopenia..  40. 1983
• The use of carcinoembryonic antigen for identification of human tumor cells in malignant effusions..  40. 1983
• Effect of lithium carbonate on the neutropenia caused by chemotherapy: a preliminary clinical trial..  34. 1977
• Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. 2017
• Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. 2016
• Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. 2014
• Metastatic colorectal cancer: from improved survival to potential cure. 2010
• Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. 2009
• Sexual oncology: sexual health issues in women with cancer. 2007
• The evolving role of gemcitabine in the management of breast cancer. 2001
• Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. 2000

Identity

ISO Abbreviation

• Oncology

Linking ISSN

• 0030-2414

International Standard Serial Number (ISSN)

• 0030-2414

Electronic International Standard Serial Number (EISSN)

• 1423-0232